The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets

Area of Science:

• Neuroscience
• Pharmacology
• Primate Models

Background:

• Glutamate receptor antagonists have shown mixed results in MPTP-treated primates for Parkinson's disease.
• Understanding NMDA receptor antagonist effects is crucial for developing new antiparkinsonian therapies.

Purpose of the Study:

• To investigate the effects of the novel NMDA antagonist CGP40.116 in MPTP-treated marmosets.
• To determine if CGP40.116 can enhance the antiparkinsonian effects of L-DOPA.

Main Methods:

• Systemic administration of CGP40.116 (25-250 µg/kg) to three adult MPTP-treated marmosets.
• CGP40.116 was administered alone and co-administered with a subthreshold dose of L-DOPA (2 mg/kg).

Main Results:

• CGP40.116 alone did not affect locomotor activity.
• When co-administered with L-DOPA, CGP40.116 significantly increased locomotor activity.

Conclusions:

• The NMDA antagonist CGP40.116 shows potential for enhancing L-DOPA's antiparkinsonian effects.
• CGP40.116 may be a valuable adjunct therapy for Parkinson's disease by improving motor function.